Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Net Margin (2021 - 2025)

Historic Net Margin for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to 10.19%.

  • Kiniksa Pharmaceuticals International's Net Margin rose 215000.0% to 10.19% in Q3 2025 from the same period last year, while for Sep 2025 it was 6.01%, marking a year-over-year increase of 277600.0%. This contributed to the annual value of 10.21% for FY2024, which is 121400.0% up from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Net Margin stood at 10.19% for Q3 2025, which was up 215000.0% from 11.37% recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Net Margin peaked at 226.05% during Q3 2022, and registered a low of 539.5% during Q2 2021.
  • Its 5-year average for Net Margin is 61.89%, with a median of 21.42% in 2023.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Net Margin skyrocketed by 4785800bps in 2022, and later tumbled by -2467100bps in 2023.
  • Kiniksa Pharmaceuticals International's Net Margin (Quarter) stood at 235.15% in 2021, then surged by 75bps to 59.7% in 2022, then grew by 1bps to 59.05% in 2023, then surged by 88bps to 7.25% in 2024, then skyrocketed by 241bps to 10.19% in 2025.
  • Its Net Margin was 10.19% in Q3 2025, compared to 11.37% in Q2 2025 and 6.2% in Q1 2025.